Recombinant

Recombinant Anti-PD1 antibody [NAT105] (ab234444)

Submit a review Submit a question References (1)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [NAT105] (ab234444)
  • Immunocytochemistry/ Immunofluorescence - Anti-PD1 antibody [NAT105] (ab234444)
  • Flow Cytometry (Intracellular) - Anti-PD1 antibody [NAT105] (ab234444)
  • Western blot - Anti-PD1 antibody [NAT105] (ab234444)
  • Anti-PD1 antibody [NAT105] (ab234444)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Mouse monoclonal [NAT105] to PD1
  • Suitable for: Flow Cyt (Intra), ICC/IF, WB, IHC-P
  • Reacts with: Human

Conjugates logo Related conjugates and formulations

Alexa Fluor® 555 Alexa Fluor® 647 Carrier Free

Overview

  • Product name

    Anti-PD1 antibody [NAT105]
    See all PD1 primary antibodies

  • Description

    Mouse monoclonal [NAT105] to PD1

  • Host species

    Mouse

  • Tested applications

    Suitable for: Flow Cyt (Intra), ICC/IF, WB, IHC-Pmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Tissue, cells or virus. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: MOLT-4 treated with 500 ng/ml ionomycin and 10 ng/ml phorbol-12-myristate-13-acetate (PMA) for 24 hours, whole cell lysate. IHC-P: Human tonsil tissue. Flow Cyt (intra): MOLT-4 cells treated with ionomycin (500 ng/ml, 24h) and PMA (10 ng/ml, 24h). ICC/IF: MOLT-4 cells treated with Ionomycin (500ng/ml, 24 h) and PMA (10ng/ml, 24 h)

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab234444 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt (Intra)
1/100.
ICC/IF
1/50.
WB
1/1000. Use under non reducing condition. Predicted molecular weight: 32 kDa.

See Western blot protocol.
IHC-P
1/50.

Perform heat-mediated antigen retrieval using Sodium citrate buffer (pH 6.0), 20 mins.
Notes
Flow Cyt (Intra)
1/100.
ICC/IF
1/50.
WB
1/1000. Use under non reducing condition. Predicted molecular weight: 32 kDa.

See Western blot protocol.
IHC-P
1/50.

Perform heat-mediated antigen retrieval using Sodium citrate buffer (pH 6.0), 20 mins.

Target

  • Function

    Possible cell death inducer, in association with other factors.

  • Involvement in disease

    Genetic variation in PDCD1 is associated with susceptibility to systemic lupus erythematosus type 2 (SLEB2) [MIM:605218]. Systemic lupus erythematosus is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. It is thought to represent a failure of the regulatory mechanisms of the autoimmune system.

  • Sequence similarities

    Contains 1 Ig-like V-type (immunoglobulin-like) domain.

  • Developmental stage

    Induced at programmed cell death.

  • Cellular localization

    Membrane.
  • Information by UniProt

  • Database links

    • Alternative names

      • CD279 antibody
      • CD279 antigen antibody
      • hPD 1 antibody
      • hPD l antibody
      • hPD-1 antibody
      • hSLE1 antibody
      • PD 1 antibody
      • PD-1 antibody
      • PD1 antibody
      • PDCD 1 antibody
      • PDCD1 antibody
      • PDCD1_HUMAN antibody
      • Programmed cell death 1 antibody
      • Programmed cell death 1 protein antibody
      • Programmed cell death protein 1 antibody
      • Protein PD 1 antibody
      • Protein PD-1 antibody
      • SLEB2 antibody
      • Systemic lupus erythematosus susceptibility 2 antibody
      see all

    Images

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [NAT105] (ab234444)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [NAT105] (ab234444)

      Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling PD1 with ab234444 at 1/50 dilution, followed by Rabbit Anti-Mouse IgG + Anti-Rabbit IgG H&L (HRP) Ready to use. Positive staining on T cells of human tonsil germinal center is observed. Performed on a Leica Biosystems BOND instrument. Counter stained with hematoxylin.

    • Immunocytochemistry/ Immunofluorescence - Anti-PD1 antibody [NAT105] (ab234444)
      Immunocytochemistry/ Immunofluorescence - Anti-PD1 antibody [NAT105] (ab234444)

      Ab234444 staining PD1 in the MOLT-4 (human lymphoblastic leukemia T lymphoblast) treated with Ionomycin (500 ng/ml, 24 h) and PMA (10 ng/ml, 24 h) by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% Paraformaldehyde, permeabilized with 0.1% Triton X-100. Samples were incubated with primary antibody (1/50). ab150117 anti-mouse IgG H&L (Alexa Fluor® 488) preadsorbed (1/100) was used as the secondary antibody. 

      ab179504 Anti-beta IV Tubulin (1/200) was used as a counter stain, detected by ab150080 AlexaFluor®594 Goat anti- Rabbit secondary (1/500)

      DAPI was used as a Nuclear counter stain.

    • Flow Cytometry (Intracellular) - Anti-PD1 antibody [NAT105] (ab234444)
      Flow Cytometry (Intracellular) - Anti-PD1 antibody [NAT105] (ab234444)

      Intracellular flow cytometric analysis ofMOLT-4 (human lymphoblastic leukemia cell line) cell line treated with ionomycin (500 ng/ml, 24h) and PMA (10 ng/ml, 24h)labeling PD1 with ab234444 at 1/1000 dilution (red) and an untreated control (green) compared with aMouse monoclonalIgG1 (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) (ab150113) at 1/2000 dilution was used as the secondary antibody. Gated on viable cells. 

       

       

    • Western blot - Anti-PD1 antibody [NAT105] (ab234444)
      Western blot - Anti-PD1 antibody [NAT105] (ab234444)
      All lanes : Anti-PD1 antibody [NAT105] (ab234444) at 1/1000 dilution

      Lane 1 : Untreated MOLT-4 (human lymphoblastic leukemia cell line) whole cell lysate
      Lane 2 : MOLT-4 (human lymphoblastic leukemia cell line) treated with 500 ng/ml ionomycin and 10 ng/ml phorbol-12-myristate-13-acetate (PMA) for 24 hours, whole cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat anti-Mouse IgG (H+L) Peroxidase Peroxidase-Conjugated at 1/5000 dilution

      Predicted band size: 32 kDa


      Exposure time: 10 seconds


      Blocking/Dilution buffer: 5% NFDM/TBST.

      The expression profile observed is consistent with what has been described in the literature (PMID: 26318293)

      We recommend that the customer optimizes the blotting conditions for themselves.

    • Anti-PD1 antibody [NAT105] (ab234444)
      Anti-PD1 antibody [NAT105] (ab234444)

    Protocols

    To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

    Click here to view the general protocols

    References (1)

    Publishing research using ab234444? Please let us know so that we can cite the reference in this datasheet.

    ab234444 has been referenced in 1 publication.

    • Qiao T  et al. Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model. Front Oncol 11:632364 (2021). PubMed: 33859941

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab234444.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com